# BioSpace

Page: https://stenobird.com/podcast/biospace-6696251
Text version: https://stenobird.com/podcast/biospace-6696251.md
RSS feed: https://api.riverside.fm/hosting/3SxyDAXU.rss
Official site: https://www.biospace.com/
Author: BioSpace
Episodes: 247

## Resource

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

## Machine-readable

JSON: https://stenobird.com/v1/public/podcasts/biospace-6696251
Markdown: https://stenobird.com/podcast/biospace-6696251.md

## Episodes
- [Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup](https://stenobird.com/podcast/biospace-6696251/biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup) — 2026-07-15T07:00:00+00:00
- [Bonus: Q2 2026 Job Market Update](https://stenobird.com/podcast/biospace-6696251/bonus-q2-2026-job-market-update) — 2026-07-14T07:00:00+00:00
- [From sequence to scale: Gene editing’s new era in biologics manufacturing](https://stenobird.com/podcast/biospace-6696251/from-sequence-to-scale-gene-editing-s-new-era-in-biologics-manufacturing) — 2026-07-10T14:29:33+00:00
- [Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil](https://stenobird.com/podcast/biospace-6696251/vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil) — 2026-07-08T07:00:00+00:00
- [Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water](https://stenobird.com/podcast/biospace-6696251/sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water) — 2026-07-01T08:00:00+00:00
- [The Golden Triangle and the gaps: Rethinking UK biotech](https://stenobird.com/podcast/biospace-6696251/the-golden-triangle-and-the-gaps-rethinking-uk-biotech) — 2026-06-25T07:00:00+00:00
- [AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more](https://stenobird.com/podcast/biospace-6696251/abbvie-keeps-m-a-rolling-fda-s-reversal-train-chugs-along-bio-2026-dispatch-more) — 2026-06-24T07:00:00+00:00
- [From fragile skin to living medicine: Lessons from RDEB](https://stenobird.com/podcast/biospace-6696251/from-fragile-skin-to-living-medicine-lessons-from-rdeb) — 2026-06-18T14:03:31+00:00
- [Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more](https://stenobird.com/podcast/biospace-6696251/moderna-s-fda-adcomm-ipo-mania-biopharma-layoffs-more) — 2026-06-17T07:00:00+00:00
- [Portugal, Spain and the new biotech frontier](https://stenobird.com/podcast/biospace-6696251/portugal-spain-and-the-new-biotech-frontier) — 2026-06-10T23:00:00+00:00
- [Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence](https://stenobird.com/podcast/biospace-6696251/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence) — 2026-06-10T07:00:00+00:00
- [Rethinking hair loss treatment](https://stenobird.com/podcast/biospace-6696251/rethinking-hair-loss-treatment) — 2026-06-03T23:00:00+00:00
- [ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck](https://stenobird.com/podcast/biospace-6696251/asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck) — 2026-06-03T09:48:40+00:00
- [France’s biotech ecosystem: science, capital and scale](https://stenobird.com/podcast/biospace-6696251/france-s-biotech-ecosystem-science-capital-and-scale) — 2026-05-28T07:00:00+00:00
- [Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds](https://stenobird.com/podcast/biospace-6696251/lilly-wheels-and-deals-moderna-gets-boost-on-hantavirus-scare-asco-excitement-builds) — 2026-05-27T07:00:00+00:00
- [Inside Germany’s biotech capital infrastructure and innovation engine](https://stenobird.com/podcast/biospace-6696251/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine) — 2026-05-21T07:00:00+00:00
- [FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum](https://stenobird.com/podcast/biospace-6696251/fda-s-absent-leaders-the-millions-pharma-ceos-make-and-pancreatic-cancer-s-momentum) — 2026-05-20T07:00:00+00:00
- [From MSCs to iPSCs: building the cell therapy future](https://stenobird.com/podcast/biospace-6696251/from-mscs-to-ipscs-building-the-cell-therapy-future) — 2026-05-14T07:00:00+00:00
- [Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay](https://stenobird.com/podcast/biospace-6696251/makary-s-out-at-fda-sanofi-s-priority-voucher-issues-top-exec-pay) — 2026-05-13T07:00:00+00:00
- [Fibrosis, IPF and the search for better therapies](https://stenobird.com/podcast/biospace-6696251/fibrosis-ipf-and-the-search-for-better-therapies) — 2026-05-07T07:00:00+00:00
- [Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening](https://stenobird.com/podcast/biospace-6696251/pfizer-lilly-more-report-q1-fda-names-acting-cber-director-and-an-als-awakening) — 2026-05-06T10:16:27+00:00
- [What makes life science angel investment work?](https://stenobird.com/podcast/biospace-6696251/what-makes-life-science-angel-investment-work) — 2026-04-30T05:00:00+00:00
- [Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions](https://stenobird.com/podcast/biospace-6696251/q1-earnings-take-off-lilly-strikes-deals-regeneron-notches-historic-approval-fda-raises-questions) — 2026-04-29T07:00:00+00:00
- [The next era of diabetes management](https://stenobird.com/podcast/biospace-6696251/the-next-era-of-diabetes-management) — 2026-04-23T07:50:23+00:00
- [Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win](https://stenobird.com/podcast/biospace-6696251/trump-s-psychedelics-push-lilly-s-up-to-7b-car-t-deal-replimune-s-saga-and-denali-s-big-win) — 2026-04-22T10:30:06+00:00
- [Funding the Future of European Biotech](https://stenobird.com/podcast/biospace-6696251/funding-the-future-of-european-biotech) — 2026-04-16T21:26:40+00:00
- [J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer](https://stenobird.com/podcast/biospace-6696251/j-j-targets-100b-revenue-replimune-rebuffed-again-and-a-revolution-in-pancreatic-cancer) — 2026-04-15T07:00:00+00:00
- [Bonus: Q1 2026 Job Market Update](https://stenobird.com/podcast/biospace-6696251/bonus-q1-2026-job-market-update) — 2026-04-14T07:00:00+00:00

## Actions

Episode pages expose an explicit `request_transcript` action. A page view does not automatically enqueue transcription.